Updated result from the phase 2 PHAROS study: has the sustained efficacy and tolerability of encorafenib plus binimetinib been demonstrated in patients with BRAF V600E-mutant metastatic non-small-cell lung cancer?

Authors

Kimio Yonesaka

Institutions

Kindai University (JP)

Publication Details

Journal: Journal of Thoracic Disease
Published: 2025-12-01
DOI: https://doi.org/10.21037/jtd-2025-1908
Primary Topic: Melanoma and MAPK Pathways
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Updated result from the phase 2 PHAROS study: has the sustained efficacy and tolerability of encorafenib plus binimetinib been demonstrated in patients with BRAF V600E-mutant metastatic non-small-cell lung cancer?

Kimio Yonesaka

Dec 1, 2025

Journal of Thoracic Disease

Melanoma and MAPK Pathways

article

Updated result from the phase 2 PHAROS study: has the sustained efficacy and tolerability of encorafenib plus binimetinib been demonstrated in patients with BRAF V600E-mutant metastatic non-small-cell lung cancer?

Kimio Yonesaka

December 1, 2025article en

Abstract

Journal of Thoracic DiseaseVol. 17(12)

Kindai University (JP)

Good health and well-being

Openalex Percentile: Top 35%

Melanoma and MAPK Pathways

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.